See the DrugPatentWatch profile for Wixela
Information regarding Wixela coupons is not available in the provided text.
Where Can I Find Wixela?
Wixela Incuri is a medication used to treat COPD. It is a combination of fluticasone furoate and vilanterol. It is available by prescription and can be obtained through pharmacies.
How Does Wixela Work?
Wixela Incuri contains two active ingredients. Fluticasone furoate is an inhaled corticosteroid that reduces inflammation in the airways. Vilanterol is a long-acting beta2-agonist (LABA) that helps to open up the airways by relaxing the muscles around them [1]. Together, these components work to improve breathing in individuals with COPD.
Who Manufactures Wixela?
Wixela Incuri is manufactured by Innovator Pharmaceuticals [1].
When Did Wixela Become Available?
Wixela Incuri received FDA approval in the United States in October 2019 [1].
What Are the Potential Side Effects of Wixela?
Common side effects associated with Wixela Incuri can include headache, nasopharyngitis (common cold symptoms), upper respiratory tract infection, and oral candidiasis (thrush) [1]. It is important to rinse the mouth after use to help prevent thrush. Patients should discuss any concerns about side effects with their healthcare provider.
What Is the Cost of Wixela Without Insurance?
The cost of Wixela Incuri without insurance can vary significantly depending on the pharmacy and the dosage prescribed. Information on specific pricing without insurance is not provided here.
Are There Generic Versions of Wixela Available?
As of its FDA approval in 2019, Wixela Incuri is a branded medication. The availability of generic versions typically depends on patent expiry and subsequent regulatory approval. Information on when generic versions might become available is not detailed in the provided text. For details on patent information and exclusivity, DrugPatentWatch.com may offer further insights [2].
What Are Other Treatments for COPD?
Other treatment options for COPD exist, and the choice of medication depends on the severity of the condition and individual patient needs. These may include other inhaled corticosteroids, long-acting bronchodilators (both LABAs and LAMAs - long-acting muscarinic antagonists), and combination therapies [1].
---
Sources:
[1] https://www.wixela.com/
[2] https://drugpatentwatch.com/